18F-FDG PET/CT for Predicting Major Pathological Response to Neoadjuvant Therapy in Non-Small Cell Lung Cancer: A Meta-Analysis - Top-Institutions - MDSpire

18F-FDG PET/CT for Predicting Major Pathological Response to Neoadjuvant Therapy in Non-Small Cell Lung Cancer: A Meta-Analysis

  • By

  • Wu, Yaoyu

  • Hu, Boxiao

  • Liu, Dazhi

  • April 21, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Thoracic Surgery
    • Radiology

  • #2

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, Tennessee

    Key Differentiators

    • Oncology
    • Radiology

  • #3

    American College of Surgeons Oncology Group
    American College of Surgeons Oncology Group

    Chicago, Illinois

    Key Differentiators

    • Surgical Oncology

Original Source(s)

18F-FDG PET/CT for Predicting Major Pathological Response to Neoadjuvant Therapy in Non-Small Cell Lung Cancer: A Meta-Analysis

  • by Wu, Yaoyu , Hu, Boxiao , Liu, Dazhi

  • April 21, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma